Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies
Antonella Padella, Andrea Ghelli Luserna di Rorà, Giovanni Marconi, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 70

Showing 1-25 of 70 citing articles:

DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities
Dana Jurkovičová, Christiana M. Neophytou, Ana Čipak Gašparović, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14672-14672
Open Access | Times Cited: 75
Exploiting RIG-I-like receptor pathway for cancer immunotherapy
Yangfu Jiang, Hongying Zhang, Jiao Wang, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 72
Design, synthesis and biological evaluation of dual CDK9/PARP inhibitors for the treatment of cancer
Jindi Huang, Ya He, Sumeng Chen, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117367-117367
Closed Access | Times Cited: 2
The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment
Shuangying Li, Liangliang Wang, Yuanyuan Wang, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 61
hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinoma
Lei Xu, Xiao Ma, Xiuzhong Zhang, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 23
Proteomic Characterization of Acute Myeloid Leukemia for Precision Medicine
Pedro Casado, Pedro R. Cutillas
Molecular & Cellular Proteomics (2023) Vol. 22, Iss. 4, pp. 100517-100517
Open Access | Times Cited: 16
Dual-target inhibitors of PARP1 in cancer therapy: A drug discovery perspective
Jiahui Zhang, Jin Zhang, Hua Li, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 7, pp. 103607-103607
Closed Access | Times Cited: 14
Recent advances in EZH2-based dual inhibitors in the treatment of cancers
Xiaojuan Yang, Xu Lu, Yang Li
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115461-115461
Closed Access | Times Cited: 13
BUB1 Inhibition Sensitizes TNBC Cell Lines to Chemotherapy and Radiotherapy
Sushmitha Sriramulu, Shivani Thoidingjam, Farzan Siddiqui, et al.
Biomolecules (2024) Vol. 14, Iss. 6, pp. 625-625
Open Access | Times Cited: 5
Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
Shunsuke Kimura, Chun Shik Park, Lindsey E. Montefiori, et al.
Cancer Discovery (2024) Vol. 14, Iss. 10, pp. 1838-1859
Closed Access | Times Cited: 5
Poly-(ADP-ribose) serves as a scaffold for the methyltransferase METTL3/14 complex in the DNA damage response
Claudia Gonzalez-Leal, Jin Cai, Bram A F J de Groot, et al.
Nucleic Acids Research (2025) Vol. 53, Iss. 7
Open Access
Germline Variants and Characteristic Features of Hereditary Hematological Malignancy Syndrome
Hironori Arai, Hirotaka Matsui, SungGi Chi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 1, pp. 652-652
Open Access | Times Cited: 4
BUB1 Inhibition Sensitizes TNBC Cell Lines to Chemotherapy and Radiotherapy
Sushmitha Sriramulu, Shivani Thoidingjam, Farzan Siddiqui, et al.
(2024)
Open Access | Times Cited: 4
Screening of necroptosis-related genes and evaluating the prognostic capacity, clinical value, and the effect of their copy number variations in acute myeloid leukemia
Dake Wen, Ru Yan, Lin Zhang, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Genetic drivers and clinical consequences of mosaic chromosomal alterations in 1 million individuals
Kun Zhao, Yash Pershad, Hannah Poisner, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Targeting Latent HIV Reservoirs: Effectiveness of Combination Therapy with HDAC and PARP Inhibitors
Hasset Tibebe, Dacia Marquez, Aidan McGraw, et al.
Viruses (2025) Vol. 17, Iss. 3, pp. 400-400
Open Access
Identifying acute myeloid leukemia subtypes based on pathway enrichment
Ling Zhong, Jiangti Luo, Junze Dong, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
SPOP mutations increase PARP inhibitor sensitivity via CK2/PIAS1/SPOP axis in prostate cancer
Hui Zhang, Lianbao Kong, Jinhui Li, et al.
JCI Insight (2025) Vol. 10, Iss. 8
Open Access
Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints
Ornella Franzese, Grazia Graziani
Cancers (2022) Vol. 14, Iss. 22, pp. 5633-5633
Open Access | Times Cited: 17
Targeting PARP for the optimal immunotherapy efficiency in gynecologic malignancies
Tianye Li, Xinrun Wang, Shuang Qin, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 162, pp. 114712-114712
Open Access | Times Cited: 10
Targeting Proliferation Signals and the Cell Cycle Machinery in Acute Leukemias: Novel Molecules on the Horizon
Andrea Ghelli Luserna di Rorà, Mouna Jandoubi, Giovanni Martinelli, et al.
Molecules (2023) Vol. 28, Iss. 3, pp. 1224-1224
Open Access | Times Cited: 9
Targeting the DNA damage response (DDR) of cancer cells with natural compounds derived from Panax ginseng and other plants
SeokGyeong Choi, Minwook Shin, Woo‐Young Kim
Journal of Ginseng Research (2024) Vol. 49, Iss. 1, pp. 1-11
Open Access | Times Cited: 3
Micelle encapsulation zinc‐doped copper oxide nanocomposites reverse Olaparib resistance in ovarian cancer by disrupting homologous recombination repair
Jingyan Yi, Xin Luo, Jinshan Xing, et al.
Bioengineering & Translational Medicine (2023) Vol. 8, Iss. 3
Open Access | Times Cited: 8
The m6A regulator KIAA1429 stabilizes RAB27B mRNA and promotes the progression of chronic myeloid leukemia and resistance to targeted therapy
Fangyi Yao, Fangmin Zhong, Junyao Jiang, et al.
Genes & Diseases (2023) Vol. 11, Iss. 2, pp. 993-1008
Open Access | Times Cited: 7
Targetable lesions and proteomes predict therapy sensitivity through disease evolution in pediatric acute lymphoblastic leukemia
Amanda Lorentzian, Jenna Rever, Enes K. Ergin, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top